Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioAdvance Capital is an evergreen venture capital fund established to support early-stage life-science companies focused on improving human health. Founded in Conshohocken, Pennsylvania, the firm primarily invests in companies located in the Mid-Atlantic region of the United States, specifically along the I-95 corridor between New York City and Washington, D.C. The organization aims to fuel innovation in the life sciences sector by providing crucial early-stage funding and strategic support to entrepreneurs.
Currently, BioAdvance Capital manages a diverse portfolio of over 120 companies and has attracted more than $4.4 billion in follow-on funding for its portfolio companies. The firm is committed to enhancing the growth of life-science startups through its investment strategy and operational support, ensuring that these companies can reach critical milestones that make them attractive to larger venture capital firms.
BioAdvance Capital invests in early-stage life-science companies, particularly in sectors such as Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. The firm primarily targets seed and Series A investment opportunities, providing funding that enables companies to reach critical milestones. Typical check sizes range from $500,000 to $1,500,000, with the potential to commit up to $5 million over the lifecycle of a company.
BioAdvance Capital seeks to partner with entrepreneurs who are dedicated to enhancing human health through various life science innovations. The organization emphasizes the importance of strategic support alongside financial investment, aiming to create a strong foundation for startups to thrive in a competitive market.
BioAdvance Capital has invested in over 120 companies, with notable portfolio companies including:
These companies have collectively attracted over $4.4 billion in follow-on funding, demonstrating the effectiveness of BioAdvance Capital's investment strategy in the life sciences sector.
Shahram Hejazi, Ph.D. - Managing Director & CEO. Hejazi has extensive experience in the life sciences sector and has led numerous successful investments in early-stage companies.
Gregory Harriman, M.D. - Partner. Harriman brings a medical background and expertise in therapeutics, contributing to the firm's investment decisions.
David Shin, M.D. - Partner. Shin has a strong background in healthcare investments and plays a key role in evaluating potential portfolio companies.
To pitch to BioAdvance Capital, founders should use the contact form available on their website. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. BioAdvance Capital typically responds within a few weeks, and while warm introductions can be beneficial, they are not strictly necessary.
In recent months, BioAdvance Capital has been active in the life sciences sector, publishing blog posts that highlight significant collaborations and advancements. Topics covered include strategic partnerships in cell therapy and AI applications in healthcare. The firm has also discussed acquisitions that enhance health technology platforms, showcasing its engagement with current trends in the industry.
These updates are released approximately once a month, reflecting BioAdvance Capital's commitment to keeping its stakeholders informed about developments in the life sciences sector.
What are BioAdvance Capital's investment criteria?
BioAdvance Capital focuses on early-stage life-science companies in sectors such as therapeutics, medical devices, digital health, diagnostics, and research tools. They primarily invest in seed and Series A rounds.
How can I apply or pitch to BioAdvance Capital?
Founders can pitch their ideas through the contact form available on the BioAdvance website. It is recommended to include a detailed business plan and financial projections in the pitch deck.
What makes BioAdvance Capital different from other investors?
BioAdvance Capital is an evergreen fund, allowing for continuous investment in promising startups. They provide not only capital but also strategic support to help companies reach critical milestones.
What is the geographic scope of BioAdvance Capital's investments?
The firm primarily invests in companies located in the Mid-Atlantic region of the United States, particularly along the I-95 corridor between New York City and Washington, D.C.
What is the typical check size for investments?
BioAdvance Capital typically invests between $500,000 and $1,500,000 in early-stage companies, with the potential for larger commitments over time.
What kind of post-investment involvement does BioAdvance Capital have?
BioAdvance Capital actively engages with portfolio companies, providing mentorship and strategic guidance to help them navigate the challenges of growth and development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.